Oaktree Acquisition Corp. III Life Sciences (OACC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 38.07 means the share price is 38.07 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $266M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOaktree Acquisition Corp. III Life Sciences (OACC) trades at $10.82 with MoonshotScore 50/100 (Grade B). Market cap: $266M, Sector: Financial services.
Price as of Sep 11, 2026 · Last analyzed: May 10, 2026Analyst Coverage for OACC: OACC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OACC against Financial Services peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
OACC: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Strongest side: Momentum (6/10, Neutral). Weakest side: Valuation (3/10, Weak).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Oaktree Acquisition Corp. III Life Sciences (OACC) Financial Services Profile
Oaktree Acquisition Corp. III Life Sciences is a specialized shell company aiming to merge with or acquire businesses in the biopharmaceutical and healthcare sectors, leveraging strategic opportunities in North America and Europe to drive growth and innovation.
What Is the Investment Thesis for OACC?
Oaktree Acquisition Corp. III Life Sciences presents a unique investment thesis as a shell company with a focus on the biopharmaceutical and healthcare sectors. OACC's strategic intent to merge with or acquire companies in this space positions it well to capture significant market share. Additionally, the increasing demand for innovative medical devices and diagnostics further enhances its growth potential. As a SPAC, OACC benefits from a streamlined acquisition process, allowing for quicker entry into lucrative markets. However, potential risks include regulatory challenges and competition from established players in the healthcare sector, which could impact the success of its acquisition strategy.
Based on FMP financials and quantitative analysis
OACC Key Highlights
Market Cap of $266M indicates a growing interest in OACC as a player in the healthcare acquisition space.
- P/E ratio of 38.07 suggests investor expectations for future earnings growth in the biopharmaceutical sector.
- Beta of -0.04 indicates low volatility compared to the market, reflecting stability in its investment approach.
- No dividend yield as OACC is focused on growth through acquisitions rather than returning capital to shareholders.
- A lean workforce of three employees allows for agile decision-making and operational efficiency.
Who Are OACC's Competitors?
OACC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| HCA HCA Healthcare, Inc. | $426.98 | +1.37% | $92.4B | 815-pillar |
| BMY Bristol-Myers Squibb Company | $63.34 | -0.64% | $129B | 905-pillar |
| CEPV Cantor Equity Partners V, Inc. | $10.41 | +0.19% | $266M | 485-pillar |
| RFAI RF Acquisition Corp II | $32.00 | -0.03% | $267M | 485-pillar |
| TDAC Translational Development Acquisition Corp. | $10.90 | -0.09% | $268M | 465-pillar |
| DMAA Drugs Made In America Acquisition Corp. | $10.80 | 0.00% | $262M | 465-pillar |
| VNME Vendome Acquisition Corporation I | $10.27 | -0.10% | $257M | 525-pillar |
| RAC Rithm Acquisition Corp. | $10.57 | -0.28% | $250M | 505-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OACC's Key Strengths?
Focused strategy on high-growth healthcare sectors.
- Lean operational structure for efficient management.
- Strong potential for value creation through strategic acquisitions.
What Are OACC's Weaknesses?
Limited operational history as a newly incorporated entity.
- Dependence on successful execution of acquisition strategy.
- Small team may limit capacity for large-scale operations.
What Could Drive OACC Stock Higher?
Strategic acquisition announcements in the biopharmaceutical sector expected in Q3 2026.
- Engagement with potential target companies for merger discussions.
- Market expansion initiatives into Europe planned for late 2026.
What Are the Key Risks for OACC?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 38.07 runs well above the Financial Services sector’s ~17.50x, leaving little room for a miss.
- Regulatory hurdles that may delay acquisition processes.
- Competition from other SPACs and established healthcare firms.
- Market volatility impacting investor confidence in SPACs.
What Are the Growth Opportunities for OACC?
- OACC's focus on acquiring companies in this space positions it to benefit from this growth, with potential acquisitions that could significantly enhance its market presence and revenue streams.
- OACC can capitalize on this trend by targeting innovative medical device companies that are poised for expansion, thereby enhancing its portfolio and competitive advantage.
- Growth opportunity 3: Diagnostics is a rapidly evolving sector, projected to reach $80 billion by 2026. OACC's strategy to acquire companies specializing in diagnostics could allow it to tap into this lucrative market, especially with the rising demand for early disease detection and personalized healthcare solutions.
- Growth opportunity 4: The specialized healthcare services market is anticipated to grow significantly, driven by an aging population and increased health awareness. OACC's focus on this sector can lead to strategic acquisitions that address these demographic trends, positioning the company for long-term growth.
- Growth opportunity 5: Expansion into European markets presents a significant opportunity, as the healthcare sector in Europe is projected to grow at a CAGR of 5.5% through 2026. By targeting European biopharmaceutical and medical device companies, OACC can diversify its portfolio and enhance its growth trajectory.
What Are OACC's Competitive Advantages?
- Specialization in high-growth sectors like biopharmaceuticals and medical devices.
- Agile operational structure allows for quick decision-making and execution.
- Access to a network of industry experts and advisors for strategic insights.
- Ability to leverage market trends to identify lucrative acquisition targets.
- Focus on North American and European markets enhances competitive positioning.
What Does OACC Do?
Oaktree Acquisition Corp. III Life Sciences was incorporated in 2024 and is headquartered in Los Angeles, California. The company operates as a special purpose acquisition company (SPAC), focusing on effecting mergers, share exchanges, asset acquisitions, and reorganizations with businesses in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. With a lean team of three employees, OACC is strategically positioned to identify and acquire high-potential companies within these rapidly evolving industries. The firm targets opportunities primarily in North America and Europe, where it aims to leverage market dynamics and technological advancements to foster growth. By concentrating on sectors that are critical to healthcare innovation, OACC is poised to capitalize on the increasing demand for medical advancements and healthcare solutions. The company's focus on biopharmaceuticals and medical devices aligns with global trends emphasizing health technology and patient-centric care, making it a relevant player in the financial services landscape dedicated to healthcare investment.
What Products and Services Does OACC Offer?
- Focus on effecting mergers and acquisitions in the biopharmaceutical and healthcare sectors.
- Identify and evaluate potential target companies for acquisition.
- Leverage market opportunities in North America and Europe for strategic growth.
- Engage in asset acquisitions, share exchanges, and reorganizations.
- Operate as a shell company with a lean team for efficient decision-making.
- Aim to create value through strategic business combinations.
How Does OACC Make Money?
- Generate revenue through successful mergers and acquisitions.
- Create value by enhancing the operational capabilities of acquired companies.
- Leverage market trends to identify high-potential investment opportunities.
- Utilize capital raised through public offerings to fund acquisitions.
- Focus on sectors with high growth potential to maximize returns.
What Industry Does OACC Operate In?
The shell companies industry, particularly SPACs, has gained significant traction as an alternative route to public markets for private companies, especially in the healthcare sector. The global SPAC market has seen explosive growth, with healthcare-focused SPACs attracting substantial capital due to the increasing demand for innovative healthcare solutions. Oaktree Acquisition Corp. III Life Sciences is positioned within this trend, targeting high-growth sectors such as biopharmaceuticals and medical devices, which are expected to grow at a CAGR of over 7% through 2025. The competitive landscape includes various SPACs and traditional private equity firms, but OACC's specialized focus on healthcare provides a distinct advantage.
Who Are OACC's Key Customers?
- Target emerging biopharmaceutical companies seeking capital and strategic partnerships.
- Engage with innovative medical device firms looking for growth opportunities.
- Collaborate with diagnostic companies focused on developing cutting-edge technologies.
- Work with specialized healthcare service providers aiming to expand their market reach.
- Attract institutional investors interested in healthcare sector investments.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 100% of our measures
- ● Price is current
- ● Latest filing 30 days ago
- ● No analyst coverage
Why 50?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.48 Share dilution (Growth)
- +0.37 Return on assets (Business Quality)
- +0.35 Earnings growth (Growth)
What is holding it back
- -0.48 5-year revenue per share (Growth)
- -0.44 Operating income growth (Growth)
- -0.38 Gross margin (Business Quality)
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 46 |
| 2026-08-26 | 46 |
| 2026-08-29 | 45 |
| 2026-09-01 | 50 |
| 2026-09-04 | 50 |
| 2026-09-07 | 50 |
| 2026-09-10 | 50 |
What changed?
The grade moved from 46 to 50 (+4).
What moved it up or down:
- +33 Financial Safety
- +2 Momentum
Held back by:
- -7 Growth Durability
- -1 Valuation
Over the same 18 days the stock moved +0.4%.
Company Profile
Oaktree Acquisition Corp. III Life Sciences operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Los Angeles, US. The company is led by CEO Zaid Pardesi. OACC has traded publicly since 2024.
Key Financial Metrics
Return on equity for Oaktree Acquisition Corp. III Life Sciences stands at 3.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.4%, showing how much profit it generates from its asset base. OACC trades at a trailing price-to-earnings ratio of 38.07, above the Financial Services sector average of ~17.50x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.4%, the inverse of the P/E and a quick read on earnings relative to price.
OACC Valuation & Market Position
With a $266M market cap, Oaktree Acquisition Corp. III Life Sciences sits in the micro-cap segment of the market. Relative to its peer group, OACC's quantitative score of 50/100 is roughly in line with the peer average of 58/100.
Quarterly Financial Performance: Oaktree Acquisition Corp. III Life Sciences
Revenue for Oaktree Acquisition Corp. III Life Sciences came in at $0 during Q2 FY2026. The company recorded net income of $1.6M, with diluted EPS of $0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Financial Services. Across the four most recent quarters, OACC averaged $0.08 in diluted EPS.
Financial Health
Oaktree Acquisition Corp. III Life Sciences's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 18.17 places it in the safe zone, indicating low near-term bankruptcy risk.
Insider Activity
The most recent 4 insider filings for Oaktree Acquisition Corp. III Life Sciences break down as 2 sales and 2 purchases. On net that is roughly 225K shares disposed (about $340K), a signal worth weighing alongside the fundamentals.
OACC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focused strategy on high-growth healthcare sectors.
- Lean operational structure for efficient management.
- Strong potential for value creation through strategic acquisitions.
- Upcoming: Strategic acquisition announcements in the biopharmaceutical sector expected in Q3 2026.
Bear Case
- Limited operational history as a newly incorporated entity.
- Dependence on successful execution of acquisition strategy.
- Small team may limit capacity for large-scale operations.
- Potential: Regulatory hurdles that may delay acquisition processes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | $2M | $0.08 |
| Q1 FY2026 | $0 | $1M | $0.07 |
| Q4 FY2025 | $0 | $2M | $0.07 |
| Q3 FY2025 | $0 | $2M | $0.10 |
Q2 FY2026 · filed 12 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
OACC Latest News
No recent news available for OACC.
OACC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for OACC.
Price Targets
Wall Street price target analysis for OACC.
OACC MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. OACC scores 50/100 (Grade B): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Leadership: Zaid Pardesi
CEO
Zaid Pardesi has a robust background in finance and strategic management, with extensive experience in the healthcare investment sector. He has held various leadership roles in financial services, focusing on mergers and acquisitions. Pardesi holds an MBA from a prestigious institution and has been involved in numerous successful transactions in his career.
Track Record: Under Zaid Pardesi's leadership, Oaktree Acquisition Corp. III Life Sciences aims to establish a strong presence in the healthcare acquisition space, leveraging his expertise to identify and execute value-driven mergers.
OACC Financial Services Stock FAQ
What does the AI Score mean for OACC?
OACC holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is OACC a good stock?
Stock Expert AI does not rate OACC buy, sell or hold. Oaktree Acquisition Corp. III Life Sciences carries a MoonshotScore of 50/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about OACC stock?
Analysts generally view Oaktree Acquisition Corp. III Life Sciences as a speculative investment due to its status as a SPAC. Key valuation metrics such as a P/E ratio of 38.07 indicate expectations for future growth.
What are the key factors to evaluate for OACC?
Oaktree Acquisition Corp. III Life Sciences (OACC) holds a MoonshotScore of 50/100 (moderate). P/E: 38.07x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does OACC data refresh on this page?
OACC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OACC's recent stock price performance?
Oaktree Acquisition Corp. III Life Sciences (OACC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused strategy on high-growth healthcare sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OACC overvalued or undervalued right now?
Oaktree Acquisition Corp. III Life Sciences (OACC) trades at 38.07x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of OACC?
Yes, most major brokerages offer fractional shares of Oaktree Acquisition Corp. III Life Sciences (OACC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track OACC's earnings and financial reports?
Oaktree Acquisition Corp. III Life Sciences (OACC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for OACC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of May 2026.